B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215

Benzinga · 3d ago
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $217 to $215.